UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 220

Sortiert nach

Review article: the burden of hepatic encephalopathy

Alimentary pharmacology & therapeutics, 2007-02, Vol.25 (s1), p.3-9

POORDAD, F. F.

2007

Volltextzugriff (PDF)

Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents

Journal of viral hepatitis, 2012-07, Vol.19 (7), p.449-464

2012

Volltextzugriff (PDF)

Interferon-free, direct-acting antiviral therapy for chronic hepatitis C

Journal of viral hepatitis, 2015-11, Vol.22 (11), p.861-870

2015

Volltextzugriff (PDF)

Review article: thrombocytopenia in chronic liver disease

Alimentary pharmacology & therapeutics, 2007-11, Vol.26 (s1), p.5-11

POORDAD, F.

2007

Volltextzugriff (PDF)

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial

The Lancet (British edition), 2014-02, Vol.383 (9916), p.515-523

2014

Volltextzugriff (PDF)

Rifaximin Is Safe and Well Tolerated for Long-term Maintenance of Remission From Overt Hepatic Encephalopathy

Clinical gastroenterology and hepatology, 2014-08, Vol.12 (8), p.1390-1397.e2

2014

Volltextzugriff (PDF)

Hepatitis C infection and the patient with end-stage renal disease

Hepatology (Baltimore, Md.), 2002-07, Vol.36 (1), p.3-10

2002

Volltextzugriff (PDF)

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial

The Lancet infectious diseases, 2013-05, Vol.13 (5), p.401-408

2013

Volltextzugriff (PDF)

Review article: the role of rapid virological response in determining treatment duration for chronic hepatitis C

Alimentary pharmacology & therapeutics, 2010-06, Vol.31 (12), p.1251-1267

POORDAD, F. F.

2010

Volltextzugriff (PDF)

Rapid Virologic Response: A New Milestone in the Management of Chronic Hepatitis C

Clinical infectious diseases, 2008-01, Vol.46 (1), p.78-84

2008

Volltextzugriff (PDF)

Presentation and complications associated with cirrhosis of the liver

Current medical research and opinion, 2015-05, Vol.31 (5), p.925-937

Poordad, Fred F.

2015

Volltextzugriff (PDF)

Review article: diagnosis and treatment of non‐alcoholic fatty liver disease

Alimentary pharmacology & therapeutics, 2008-09, Vol.28 (5), p.503-522

2008

Volltextzugriff (PDF)

Hepatitis C Virus Treatment-Related Anemia Is Associated With Higher Sustained Virologic Response Rate

Gastroenterology (New York, N.Y. 1943), 2010-11, Vol.139 (5), p.1602-1611.e1

2010

Volltextzugriff (PDF)

Randomised clinical trial: rifaximin improves health‐related quality of life in cirrhotic patients with hepatic encephalopathy – a double‐blind placebo‐controlled study

Alimentary pharmacology & therapeutics, 2011-10, Vol.34 (8), p.853-861

2011

Volltextzugriff (PDF)

Screening for hepatitis B in chemotherapy patients: survey of current oncology practices

Alimentary pharmacology & therapeutics, 2010-01, Vol.31 (2), p.240-246

2010

Volltextzugriff (PDF)

Simeprevir, daclatasvir and sofosbuvir for hepatitis C virus‐infected patients with decompensated liver disease

Journal of viral hepatitis, 2017-04, Vol.24 (4), p.287-294

2017

Volltextzugriff (PDF)

A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C

Journal of viral hepatitis, 2012-05, Vol.19 (s2), p.1-26

2012

Volltextzugriff (PDF)

Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B

Journal of viral hepatitis, 2010-01, Vol.17 (1), p.16-22

2010

Volltextzugriff (PDF)

6-thioguanine can cause serious liver injury in inflammatory bowel disease patients

Gastroenterology (New York, N.Y. 1943), 2003-08, Vol.125 (2), p.298-303

2003

Volltextzugriff (PDF)

484 PREDICTORS OF SUSTAINED VIROLOGIC RESPONSE AMONG GENOTYPE 1 PREVIOUS NON-RESPONDERS AND RELAPSERS TO PEGINTERFERON/RIBAVIRIN WHEN RE-TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN

Journal of hepatology, 2011-03, Vol.54, p.S198-S199

2011

Volltextzugriff (PDF)

Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation

Liver Transplantation and Surgery, 1999-11, Vol.5 (6), p.491-496

1999

Volltextzugriff (PDF)

Safety of ABT-493 and ABT-530 Co-Administered in Patients with HCV Genotype 1–6 Infection: Results from the Surveyor-I and Surveyor-II Studies

Journal of hepatology, 2016, Vol.64 (2), p.S809-S809

2016

Volltextzugriff (PDF)

Peginterferon and Ribavirin for Treatment of Recurrent Hepatitis C Disease in HCV–HIV Coinfected Liver Transplant Recipients

American journal of transplantation, 2014-05, Vol.14 (5), p.1129-1135

2014

Volltextzugriff (PDF)

The point of care 13C-Methacetin Breath Test predicts risk of long-term liver-related death or transplantation in patients with chronic liver disease: a sensitive, noninvasive monitoring tool in clinical hepatology

Journal of hepatology, 2017, Vol.66 (1), p.S668-S669

2017

Volltextzugriff (PDF)

Pharmacokinetics and safety of glecaprevir/pibrentasvir in adults with chronic genotype 1–6 hepatitis C virus infection and compensated cirrhosis: an integrated analysis

Journal of hepatology, 2017, Vol.66 (1), p.S306-S306

2017

Volltextzugriff (PDF)

1 – 25 von 220

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(212)
Mit Volltextzugriff
(208)

Publikationsform

Sprache

Englisch
(219)
Japanisch
(13)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

Gastroenterology And Hepatology
(88)
Humans
(77)
Life Sciences & Biomedicine
(72)
Science & Technology
(72)
Female
(47)
Male
(46)
Gastroenterology & Hepatology
(40)
Middle Aged
(40)
Adult
(36)
Hepatitis C, Chronic - Drug Therapy
(29)
Biological And Medical Sciences
(27)
Medical Sciences
(27)
Infectious Diseases
(25)
Drug Therapy, Combination
(22)
Treatment Outcome
(22)
Antiviral Agents - Therapeutic Use
(21)
Hepatitis
(21)
Pharmacology. Drug Treatments
(20)
Aged
(19)
Hepatitis C Virus
(19)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Review article: the burden of hepatic encephalopathy

Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents

Interferon-free, direct-acting antiviral therapy for chronic hepatitis C

Review article: thrombocytopenia in chronic liver disease

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial

Rifaximin Is Safe and Well Tolerated for Long-term Maintenance of Remission From Overt Hepatic Encephalopathy

Hepatitis C infection and the patient with end-stage renal disease

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial

Review article: the role of rapid virological response in determining treatment duration for chronic hepatitis C

Rapid Virologic Response: A New Milestone in the Management of Chronic Hepatitis C

Presentation and complications associated with cirrhosis of the liver

Review article: diagnosis and treatment of non‐alcoholic fatty liver disease

Hepatitis C Virus Treatment-Related Anemia Is Associated With Higher Sustained Virologic Response Rate

Randomised clinical trial: rifaximin improves health‐related quality of life in cirrhotic patients with hepatic encephalopathy – a double‐blind placebo‐controlled study

Screening for hepatitis B in chemotherapy patients: survey of current oncology practices

Simeprevir, daclatasvir and sofosbuvir for hepatitis C virus‐infected patients with decompensated liver disease

A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C

Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B

6-thioguanine can cause serious liver injury in inflammatory bowel disease patients

484 PREDICTORS OF SUSTAINED VIROLOGIC RESPONSE AMONG GENOTYPE 1 PREVIOUS NON-RESPONDERS AND RELAPSERS TO PEGINTERFERON/RIBAVIRIN WHEN RE-TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN

Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation

Safety of ABT-493 and ABT-530 Co-Administered in Patients with HCV Genotype 1–6 Infection: Results from the Surveyor-I and Surveyor-II Studies

Peginterferon and Ribavirin for Treatment of Recurrent Hepatitis C Disease in HCV–HIV Coinfected Liver Transplant Recipients

The point of care 13C-Methacetin Breath Test predicts risk of long-term liver-related death or transplantation in patients with chronic liver disease: a sensitive, noninvasive monitoring tool in clinical hepatology

Pharmacokinetics and safety of glecaprevir/pibrentasvir in adults with chronic genotype 1–6 hepatitis C virus infection and compensated cirrhosis: an integrated analysis

Suchergebnisse filtern